Annovis Bio, Inc.ANVSEarnings & Financial Report
Annovis Bio, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative disorders including Alzheimer's disease and Parkinson's disease. It targets both neuronal and synaptic dysfunction, operates primarily in the U.S. biopharmaceutical market, and advances its therapeutic pipeline through clinical trials to address unmet medical needs for patients with chronic neurological conditions.
ANVS Q4 FY2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-9.7M
Net Profit
$-9.8M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.39
Annovis Bio, Inc. Q4 FY2025 Financial Summary
Annovis Bio, Inc. reported revenue of $0 for Q4 FY2025, with a net profit of $-9.8M (down 67.7% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-9.8M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
Annovis Bio, Inc. Annual Revenue by Year
Annovis Bio, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $0).
Annovis Bio, Inc. Quarterly Revenue & Net Profit History
Annovis Bio, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $0 | — | $-9.8M | N/A |
| Q3 FY2025 | $0 | — | $-7.3M | N/A |
| Q2 FY2025 | $0 | — | $-6.2M | N/A |
| Q1 FY2025 | $0 | — | $-5.5M | N/A |
| Q4 FY2024 | $0 | — | $-5.9M | N/A |
| Q3 FY2024 | $0 | — | $-12.6M | N/A |
| Q2 FY2024 | $0 | — | $-5.0M | N/A |
| Q1 FY2024 | $0 | — | $-1.1M | N/A |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $7.8M | $5.0M | $14.4M | $13.9M | $26.7M | $21.5M | $17.2M | $21.1M |
| Liabilities | $11.2M | $6.8M | $7.3M | $4.6M | $2.7M | $3.1M | $4.0M | $4.2M |
| Equity | $-3.4M | $-1.8M | $7.1M | $9.3M | $24.1M | $18.3M | $13.2M | $16.9M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-7.0M | $-3.4M | $-3.2M | $-8.3M | $-8.1M | $-5.1M | $-3.5M | $-8.9M |